In a significant advancement for pediatric neuromodulation therapy, NeurAxis, Inc. (NYSE American: NRXS) has successfully completed a $5 million registered direct offering, bolstering its commercial expansion following breakthrough FDA clearance for expanded treatment indications. The transaction, involving 1,538,461 shares of common stock at $3.25 per share, demonstrates strong investor confidence in the company’s proprietary neuromodulation platform.
